ActiveSight Signs Protein Crystallography Agreement with Novo Nordisk
News Jan 24, 2006
ActiveSight will co-crystallize Novo Nordisk proprietary molecules with proteins expressed by ActiveSight.
"We are very pleased to add a company of Novo Nordisk's stature to our growing customer base," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
"We look forward to supplying their scientists with structural information to accelerate their discovery efforts."
This is the first announced agreement of 2006 for the protein crystallography services provider, which was founded in 2003.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019